Understanding how YES1 affects triple negative breast cancer
Discovering the role of YES1 in triple negative breast cancer
This study is looking at a protein called YES1 to see how it helps triple negative breast cancer grow and survive, with the hope that understanding this could lead to better treatments for patients facing this tough type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11256896 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called YES1 in triple negative breast cancer (TNBC), a type of breast cancer known for its aggressive nature and limited treatment options. The study aims to understand how YES1 contributes to the growth and survival of TNBC cells, particularly by maintaining the levels of another important protein, Epidermal Growth Factor Receptor (EGFR). By exploring the unique functions of YES1, the researchers hope to identify new vulnerabilities in TNBC that could lead to better treatment strategies. Patients may benefit from insights that could improve therapeutic approaches for this challenging cancer type.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who may be seeking new treatment options.
Not a fit: Patients with other types of breast cancer or those who do not have a diagnosis of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that specifically target YES1, potentially improving outcomes for patients with triple negative breast cancer.
How similar studies have performed: Previous research has shown that targeting specific proteins in cancer cells can lead to significant advancements in treatment, suggesting that this approach may also be promising for TNBC.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Keri, Ruth a. — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Keri, Ruth a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.